Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. Blaise Coleman

Market Cap

NaN undefined USD

Sector

Healthcare

Website

https://www.endo.com

Last Update

2/22/2024, 12:00:00 PM

Description

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally.

Read More

Overview

Value

1

Growth

2

Health

38

Management

46

Analyst Opinion

57

Total

29

All Scores Out Of 100

Best Features

  • Earnings growth has improved recently
  • Has a low level of debt
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Earnings are negative
  • There is a history of diluting shareholders
  • Disliked by Twitter users
  • Poor earnings and cashflow growth
  • Dividend could be at risk

Market Peers

ENDP

Key Figures

PE Ratio (TTM)

N/A

Margin Of Safety (DCF)

N/A

Revenue Growth (5 Year Average)

-1.44%

Ratings Consensus

Neutral

Share Buybacks

-0.25%

Dividend Yeild (TTM)

N/A

Valuation

Value Score

1

  • Estimated intrinsic-value of N/A is lower than current price ( 374.40 undefined USD)
  • Free-cashflow-yeild of N/A is worse than the market average (4.7%)
  • Margin-of-safety of N/A is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: N/ANaNNaN

Current Price: 0.4 USD

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

N/Ax

Free Cashflow Yeild

N/A

PE/Earnings Growth

N/A

Price/Book

Infinityx

Growth

Growth Score

2

  • Earnings growth has improved this year
  • Free Cashflow growth has improved this year
  • 5 Year Average Revenue growth of -1.44% is lower than the market average (10.97%)
  • Revenue growth has slowed this year
  • 5 Year Average Earnings growth of -24.56% is lower than the market average (14.48%)
  • 5 Year Average Free Cashflow growth of -20.74% is lower than the market average (12.35%)

Revenue Growth

-1.44%

Earnings Growth

-24.56%

Cashflow Growth

-20.74%

Health

Health Score

38

  • Has a low level of debt
  • Assets cover liabilities
  • High financial leverage and base interest rate exposure
  • Requires debt for normal operation to be sustainable
  • Debt repayments significantly impact cashflow

Altman Z Score

N/A

Piostroski Score

N/A

Debt/Equity

0.00x

Current Assets/Liabilities

1.86x

Free Cashflow/Total Debt

0.02x

Debt/Capital

3.68x

Dividend

Secure Dividend Score

0

  • Long term dividend payout ratio of 0.00% is considered good
  • Payout ratio (TTM) of 0.00% is lower than the average (40%)
  • Dividends have shown growth over the last 5 years
  • Spending a lower percentage of their income on dividends than last 5 years
  • Dividend yeild of N/A is less than the market average (1.85%)
  • Very unsafe

Dividend Yeild

N/A

Dividend Growth

0.00%

Payout Ratio (Earnings)

0.00%

Payout Ratio (Cashflow)

0.00%

Management

Management Score

46

  • Has issued new shares to finance growth when share price is high
  • Return-on-capital-employed of -26.88% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity
  • Return-on-equity of 0.00% is lower than the market average (15%)

Average Buybacks/Dilution

-0.25%

Recent Buybacks/Dilution

-100.00%

5 Year Price Volitility

60.54%

Return On Assets

0.00%

Return On Capital Employed

-26.88%

Return On Equity

0.00%

Return On Free Cashflow

N/A

Return On Investments

N/A

Social Sentiment

Social Sentiment Score

0

Twitter Sentiment

N/A

Stocktwits Sentiment

N/A

Analysts

Analyst Opinion

57

  • Ratings consensus is Neutral

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Endo International plc

Currency

USD

Beta

1.153314

Vol Avg

0

Ceo

Mr. Blaise Coleman

Cik

0001593034

Cusip

Exchange

NASDAQ Global Select

Full Time Employees

3103

Industry

Drug Manufacturers—Specialty & Generic

Sector

Healthcare

Ipo Date

2014-03-03

Address

Minerva House, Simmonscourt Road

City

DUBLIN

State

DUBLIN

Country

IE

Zip

4

Phone

35312682000

Analysis Last Updated

2/22/2024, 12:00:00 PM

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies